Abstract
Introduction The prognostic value of low estrogen and progesterone receptors expression (ER/PgR 1%-10%) in early breast cancer patients is still unclear. Patients and Methods We retrospectively analyzed 1424 consecutive patients with HER2/neu-negative and low endocrine receptors expression early breast cancer, submitted to surgery at the European Institute of Oncology between January 1995 and December 2009. Patients were classified according to the percentage of ER/PgR expression using immunohistochemistry. Group 1 with ER/PgR <1%, and group 2 with ER/PgR 1% to 10%. Results Group 1 (ER/PgR <1%) included 1300 patients, and group 2 (ER/PgR 1%-10%) 124 patients. Median follow-up time was 74 months (range, 3-192 months). The 5-year disease-free survival (DFS) rate was 74% (95% confidence interval [CI], 72%-77%) for group 1, and 79% (95% CI, 70%-86%) for group 2 (P =.16). The 5-year overall survival (OS) rate was 86% (95% CI, 84%-88%) in group 1 and 90% (95% CI, 83%-95%) in group 2 (P =.13). In patients without lymph node involvement, the 5-year OS rate was 92% (95% CI, 89.5%-93.6%) for group 1 and 98% (95% CI, 90.2%-99.8%) for group 2 (P =.061). One hundred ten patients received endocrine therapy with no significant effect on DFS (P =.36) and OS (P =.30). Conclusion The ER/PgR 1%-10% group had a slight, but not statistically significant, better prognosis than the ER/PgR
| Original language | English |
|---|---|
| Pages (from-to) | 258-264 |
| Number of pages | 7 |
| Journal | Clinical Breast Cancer |
| Volume | 14 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Adjuvant treatment
- Estrogen receptor
- Histologic subtypes
- Low endocrine responsiveness
- Overall survival
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. / Balduzzi, Alessandra; Bagnardi, Vincenzo; Rotmensz, Nicole; Dellapasqua, Silvia; Montagna, Emilia; Cardillo, Anna; Viale, Giuseppe; Veronesi, Paolo; Intra, Mattia; Luini, Alberto; Pruneri, Giancarlo; Mastropasqua, Giuseppe; Goldhirsch, Aron; Colleoni, Marco.
In: Clinical Breast Cancer, Vol. 14, No. 4, 2014, p. 258-264.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression
AU - Balduzzi, Alessandra
AU - Bagnardi, Vincenzo
AU - Rotmensz, Nicole
AU - Dellapasqua, Silvia
AU - Montagna, Emilia
AU - Cardillo, Anna
AU - Viale, Giuseppe
AU - Veronesi, Paolo
AU - Intra, Mattia
AU - Luini, Alberto
AU - Pruneri, Giancarlo
AU - Mastropasqua, Giuseppe
AU - Goldhirsch, Aron
AU - Colleoni, Marco
PY - 2014
Y1 - 2014
N2 - Introduction The prognostic value of low estrogen and progesterone receptors expression (ER/PgR 1%-10%) in early breast cancer patients is still unclear. Patients and Methods We retrospectively analyzed 1424 consecutive patients with HER2/neu-negative and low endocrine receptors expression early breast cancer, submitted to surgery at the European Institute of Oncology between January 1995 and December 2009. Patients were classified according to the percentage of ER/PgR expression using immunohistochemistry. Group 1 with ER/PgR <1%, and group 2 with ER/PgR 1% to 10%. Results Group 1 (ER/PgR <1%) included 1300 patients, and group 2 (ER/PgR 1%-10%) 124 patients. Median follow-up time was 74 months (range, 3-192 months). The 5-year disease-free survival (DFS) rate was 74% (95% confidence interval [CI], 72%-77%) for group 1, and 79% (95% CI, 70%-86%) for group 2 (P =.16). The 5-year overall survival (OS) rate was 86% (95% CI, 84%-88%) in group 1 and 90% (95% CI, 83%-95%) in group 2 (P =.13). In patients without lymph node involvement, the 5-year OS rate was 92% (95% CI, 89.5%-93.6%) for group 1 and 98% (95% CI, 90.2%-99.8%) for group 2 (P =.061). One hundred ten patients received endocrine therapy with no significant effect on DFS (P =.36) and OS (P =.30). Conclusion The ER/PgR 1%-10% group had a slight, but not statistically significant, better prognosis than the ER/PgR
AB - Introduction The prognostic value of low estrogen and progesterone receptors expression (ER/PgR 1%-10%) in early breast cancer patients is still unclear. Patients and Methods We retrospectively analyzed 1424 consecutive patients with HER2/neu-negative and low endocrine receptors expression early breast cancer, submitted to surgery at the European Institute of Oncology between January 1995 and December 2009. Patients were classified according to the percentage of ER/PgR expression using immunohistochemistry. Group 1 with ER/PgR <1%, and group 2 with ER/PgR 1% to 10%. Results Group 1 (ER/PgR <1%) included 1300 patients, and group 2 (ER/PgR 1%-10%) 124 patients. Median follow-up time was 74 months (range, 3-192 months). The 5-year disease-free survival (DFS) rate was 74% (95% confidence interval [CI], 72%-77%) for group 1, and 79% (95% CI, 70%-86%) for group 2 (P =.16). The 5-year overall survival (OS) rate was 86% (95% CI, 84%-88%) in group 1 and 90% (95% CI, 83%-95%) in group 2 (P =.13). In patients without lymph node involvement, the 5-year OS rate was 92% (95% CI, 89.5%-93.6%) for group 1 and 98% (95% CI, 90.2%-99.8%) for group 2 (P =.061). One hundred ten patients received endocrine therapy with no significant effect on DFS (P =.36) and OS (P =.30). Conclusion The ER/PgR 1%-10% group had a slight, but not statistically significant, better prognosis than the ER/PgR
KW - Adjuvant treatment
KW - Estrogen receptor
KW - Histologic subtypes
KW - Low endocrine responsiveness
KW - Overall survival
UR - http://www.scopus.com/inward/record.url?scp=84904617944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904617944&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2013.10.019
DO - 10.1016/j.clbc.2013.10.019
M3 - Article
VL - 14
SP - 258
EP - 264
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
IS - 4
ER -